Trevi Therapeutics Secures FDA Alignment, Advances Cough Therapies
Event summary
- Trevi Therapeutics received FDA alignment on its Phase 3 program for IPF-related chronic cough following an End-of-Phase 2 meeting.
- The company plans to initiate a Phase 2b clinical trial for refractory chronic cough (RCC) in Q2 2026.
- Trevi Therapeutics ended 2025 with $188.3 million in cash, projecting a runway into 2028.
- R&D expenses decreased in 2025 to $33.5 million, primarily due to the completion of prior-year clinical trials.
The big picture
Trevi's FDA alignment represents a significant de-risking event for its lead IPF-related cough program, potentially unlocking substantial value given the unmet need in this patient population. The company's focus on RCC and non-IPF ILD expands its addressable market, but also introduces additional clinical and regulatory hurdles. The current cash position provides breathing room, but successful execution of the upcoming trials is paramount to long-term success.
What we're watching
- Clinical Execution
- The success of the two parallel Phase 3 trials for IPF-related cough will be critical, given the agreement with the FDA hinges on their design and outcomes. Any deviations from the planned enrollment or dosing could significantly impact the timeline and potential approval.
- Cash Management
- While the current cash runway extends into 2028, the initiation of multiple Phase 2b and Phase 3 trials will accelerate burn. Monitoring the company's ability to maintain this runway without additional financing will be essential.
- Competitive Landscape
- Given the lack of FDA-approved therapies for RCC, Trevi faces a potential first-mover advantage. However, the emergence of alternative treatments or competing approaches could erode market share and impact commercial viability.
Related topics